Edding Genor Group Holdings Limited
HHKEX:69981.63
HKD
0.00
(0.00%)
ISIN
KYG3871A1004
CUSIP
G3871A100
Return %
Stock
S&P 500
1Y
-52.06
14.20
3Y
34.71
81.12
5Y
-85.32
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Xin Ni
- Full Time Employees
- 1,545
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Building 3 Shanghai SH China 201203
- IPO Date
- Oct 7, 2020
- Website
- genorbio.com
- Similar Companies
- Business
- Genor Biopharma Holdings Limited, a Cayman Islands-incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange (6998.HK), engages in the discovery, development, and commercialization of innovative biologics primarily targeting oncology and autoimmune diseases in China. Founded in December 2007 through its key operating subsidiary Genor Biopharma Co., Ltd. in Shanghai, China, where it maintains its headquarters at Building 3, 1690 Zhangheng Road, Pudong New District, the company offers a pipeline encompassing monoclonal antibodies such as geptanolimab (GB226, a PD-1 inhibitor approved for peripheral T-cell lymphoma), infliximab biosimilar (GB242), rituximab biosimilar, trastuzumab biosimilar, and bevacizumab biosimilar; bispecific and trispecific antibodies including GB261 (CD20 x CD3); small molecule drugs like lerociclib (a CDK4/6 inhibitor with NDAs accepted for breast cancer); and preclinical candidates such as GB262, GB264, GB266, GB267, and GB268 for cancer treatment, alongside STING agonist GB492. It operates mainly in China with global ambitions, serving patients through an integrated platform covering cell line development, bioprocess optimization, and analytical services; the approved product GenoMab (rituximab biosimilar) addresses cancers and autoimmune conditions. Recent developments include a proposed reverse merger with Eddingpharm (Edding Group Company Limited), announced in 2024 and progressing into 2025 with delayed circular dispatch pending regulatory approvals and shareholder votes, which would dilute existing shareholders to about 22% while granting Eddingpharm control of the Hong Kong listing and Genor's cancer portfolio; a January 2025 cooperative development agreement with Eddingpharm on trispecific antibodies GBD218 (CD3/BCMA/GPRC5D for multiple myeloma) and GBD220 (CD3/CD19); sale of global ex-China rights to a CD20/CD3 bispecific antibody for tens of millions upfront plus up to $443 million in milestones; NDA acceptances for lerociclib combinations; and a May 2025 approval in China for one of its candidates.